Reversal Agents
About
-
Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.
Load moreDirect oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.
Anticoagulant reversal should only be considered with life-threatening bleeds, with bleeds that fail to respond to usual measures, and in patients requiring urgent surgery.
Idarucizumab is licensed for dabigatran reversal. The Factor Xa inhibitor andexanet alfa has recently been licensed in the US for reversal of rivaroxaban, apixaban and edoxaban.
Load Less
Videos
-
06 April 2018 -
13 April 2017
Reversal Agents - New This Month
-
Burnett A, Siegal D, Crowther M, et alBMJ 2017;357:j2216
-
Alexander Niessner, Juan Tamargo, João Morais, et alEur Heart J (2017) 38 (22): 1710-1716.
-
Charles V. Pollack, Paul A. Reilly, Joanne van Ryn, et al
Reversal Agents - Idarucizumab for Dabigatran Reversal
-
Stephan Glund, J. Stangier, Michael Schmohl, et alBlood 2014 124:344;
-
John Eikelboom, Daniel J. Quinlan, J. van Ryn, et alCirculation. 2015;132:2412-2422.
-
Charles V. Pollack, Paul A. Reilly, Richard A. Bernstein, et alThromb Haemost 2015; 114: 198–205
-
Stephan Glund, V. Moschetti, Stephen Norris, et alThromb Haemost 2015; 113: 943–951.
Reversal Agents - Andexanet Alfa for Factor Xa Inhibitors
-
Mark Crowther, Mathur Vandana, Kitt Michael, et alBlood 2013 122:3636;
-
Mark Crowther, Gallia G. Levy, Genmin Lu, et alBlood 2014 124:4269;
-
Stuart J. Connolly, Truman J. Milling, John Eikelboom, et alN Engl J Med. 2016 Sep 22;375(12):1131-41.
Reversal Agents - Ciraparantag for Factor Xa Inhibitors
-
Jack E. Ansell, Bryan E. Laulicht, Sasha H. Bakhru, et alThromb Res. 2016 Oct;146:113-118.
-
Jack E. Ansell, Sasha H. Bakhru, Bryan E. Laulicht, et alThromb Haemost. 2017 Jan 26;117(2):238-245.
Reversal Agents - Guidelines/expert recommendations
-
Jeffrey I. WeitzSemin Respir Crit Care Med. 2017 Feb;38(1):40-50.
-
Walter Ageno, Harry R. Buller, A. Falanga, et alThromb Haemost. 2016 Nov 30;116(6):1003-1010.
-
Jerrold H. Levy, Walter Ageno, N. C. Chan, et alJ Thromb Haemost. 2016 Mar;14(3):623-7.
-
Amish N. Raval, Joaquin E. Cigarroa, Mina K. Chung, et alCirculation. 2017;135:e604-e633
